| | 214766-78-6 Basic information More.. |
| Product Name: | Degarelix | | Synonyms: | DEGARELIX;N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide acetate;D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-;Degarelix acetate(FE-200486,Degarelix);Degarelix, Degarelix acetate;Degarelix acetate salt;D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-ly;D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- | | CAS: | 214766-78-6 | | MF: | C82H103ClN18O16 | | MW: | 1632.26 | | EINECS: | 807-277-4 | | Mol File: | 214766-78-6.mol |  |
Use
The most common adverse events included injection site reactions (pain, erythema, swelling, or induration), hot flashes, increased weight, and increases in serum levels of transaminases and gamma-glutamyltransferase. In addition to being contraindicated in patients with a previous hypersensitivity to degarelix, it should not be administered to women who are or may become pregnant as fetal harm can occur. Since long-term androgen deprivation therapy prolongs the QT interval, physicians should consider whether the benefits of degarelix outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure or in patients taking antiarrhythmic medications.
- DEGARELIX
-
- 2025-06-29
- CAS:214766-78-6
- Min. Order:
- Purity: 0.99
- Supply Ability:
- Degarelix
-
- US $0.00 / g
- 2025-06-28
- CAS:214766-78-6
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
- Degarelix
-
- US $0.00-0.00 / Box
- 2025-06-27
- CAS:214766-78-6
- Min. Order: 1Box
- Purity: 99.99%
- Supply Ability: 10 Boxes
|
|
214766-78-6
Recommend Suppliers |
|